U.S. markets closed
  • S&P Futures

    3,830.75
    -8.25 (-0.21%)
     
  • Dow Futures

    31,485.00
    +20.00 (+0.06%)
     
  • Nasdaq Futures

    12,558.00
    -105.75 (-0.84%)
     
  • Russell 2000 Futures

    2,192.60
    +2.90 (+0.13%)
     
  • Crude Oil

    67.48
    +1.39 (+2.10%)
     
  • Gold

    1,702.00
    +3.50 (+0.21%)
     
  • Silver

    25.67
    +0.38 (+1.51%)
     
  • EUR/USD

    1.1906
    -0.0018 (-0.15%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • Vix

    24.66
    -3.91 (-13.69%)
     
  • GBP/USD

    1.3818
    -0.0010 (-0.07%)
     
  • USD/JPY

    108.3860
    +0.0040 (+0.00%)
     
  • BTC-USD

    50,397.50
    +678.57 (+1.36%)
     
  • CMC Crypto 200

    1,019.73
    +76.56 (+8.12%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,766.97
    -97.35 (-0.34%)
     

Oxford University to test COVID-19 vaccine response among children for first time

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Feb 13 (Reuters) - The University of Oxford has launched astudy to assess the safety and immune response of the COVID-19vaccine it has developed with AstraZeneca Plc inchildren for the first time, it said on Saturday.

The new mid-stage trial will determine whether the vaccineis effective on people between the ages of 6 and 17, accordingto an emailed statement from the university.

Around 300 volunteers will be enrolled and firstinoculations are expected this month, Oxford said.

The two-dose Oxford/AstraZeneca vaccine has been hailed as a'vaccine for the world' because it is cheaper and easier todistribute than some rivals.

AstraZeneca has a target to produce 3 billion doses thisyear and aims to produce over 200 million doses per month byApril.(Reporting by Derek Francis in Bengaluru, Editing by RosalbaO'Brien)